Receipt of a newer recombinant version of a shingles vaccine is associated with a significant delay in dementia diagnosis in older adults, a new study suggests.
The study builds on previous observations of a reduction in dementia risk with the older live shingles vaccine and reports a delay in dementia diagnosis of 164 days with the newer recombinant version compared to the live vaccine.
"Given the prevalence of dementia, a delay of 164 days in diagnosis would not be a trivial effect at the public health level. It's a big enough effect that if there is a causality it feels meaningful," senior author, Paul Harrison, DM, FRCPsych , professor of psychiatry at the University of Oxford, United Kingdom, said.
But Harrison stressed that the study had not proven that the shingles vaccine reduced dementia risk.
"The design of the study allows us to do away with many of the confounding effects we usually see in observational studies, but this is still an observational study, and as such it cannot prove a definite causal effect," he said.
The study was published online on July 25 in Nature Medicine.
'Natural Experiment'
Given the risk for deleterious consequences of shingles, vaccination is now recommended for older adults in many countries. The previously used live shingles vaccine (Zostavax) is being replaced in most countries with the new recombinant shingles vaccine (Shingrix), which is more effective at preventing shingles infection.
The current study made use of a "natural experiment" in the United States, which switched over from use of the live vaccine to the recombinant vaccine in October 2017.
Researchers used electronic heath records to compare the incidence of a dementia diagnosis in individuals who received the live shingles vaccine prior to October 2017 to those who received the recombinant version after the United States made the switch.
They also used propensity-score matching to further control for confounding factors, comparing 103,837 individuals who received a first dose of the live shingles vaccine between October 2014 and September 2017 with the same number of matched people who received the recombinant vaccine between November 2017 and October 2020.
Results showed that within the 6 years after vaccination, the recombinant vaccine was associated with a delay in the diagnosis of dementia compared with the live vaccine. Specifically, receiving the recombinant vaccine was associated with a 17% increase in diagnosis-free time, translating to 164 additional days lived without a diagnosis of dementia in those subsequently affected.
As an additional control, the researchers also found significantly lower risks for dementia in individuals receiving the new recombinant shingles vaccine vs two other vaccines commonly used in older people: influenza and tetanus/diphtheria/pertussis vaccines, with increases in diagnosis-free time of 14%-27%.
Reduced Risk or Delayed Diagnosis?
S peaking at a Science Media Centre press conference on the study, lead author Maxime Taquet, PhD, FRCPsych, clinical lecturer in psychiatry at the University of Oxford, noted that the total number of dementia cases were similar in the two shingles vaccine groups by the end of the 6-year follow-up period but there was a difference in the time at which they received a diagnosis of dementia.
"The study suggests that rather than actually reducing dementia risk, the recombinant vaccine delays the onset of dementia compared to the live vaccine in patients who go on to develop the condition," he explained.
But when comparing the recombinant vaccine with the influenza and tetanus/diphtheria/pertussis vaccines there was a clear reduction in dementia risk itself, Taquet reported.
"It might well be that the live vaccine has a potential effect on the risk of dementia itself and therefore the recombinant vaccine only shows a delay in dementia compared to the live vaccine, but both of them might decrease the overall risk of dementia," he suggested.
But the researchers cautioned that this study could not prove causality.
"While the two groups were very carefully matched in terms of factors that might influence the development of dementia, we still have to be cautious before assuming that the vaccine is indeed causally reducing the risk of onset of dementia," Harrison warned.
The researchers say the results would need to be confirmed in a randomized trial, which may have to be conducted in a slightly younger age group, as currently shingles vaccine is recommended for all older individuals in the United Kingdom.
Vaccine recommendations vary from country to country, he added. In the United States, the Centers for Disease Control and Prevention recommends the recombinant shingles vaccine for all adults aged 50 years or older.
In the meantime, it would be interesting to see whether further observational studies in other countries find similar results as this US study, Harrison said.
Mechanism Uncertain
Speculating on a possible mechanism behind the findings, Harrison suggested two plausible explanations.
"First, it is thought that the herpes virus could be one of many factors that could promote dementia, so a vaccine that stops reactivation of this virus might therefore be delaying that process," he noted.
The other possibility is that adjuvants included in the recombinant vaccine to stimulate the immune system might have played a role.
"We don't have any data on the mechanism, and thus study did not address that, so further studies are needed to look into this," Harrison said.
Stronger Effect in Women
Another intriguing finding is that the association with the recombinant vaccine and delayed dementia diagnosis seemed to be stronger in women vs men.
In the original study of the live shingles vaccine, a protective effect against dementia was shown only in women.
In the current study, the delay in dementia diagnosis was seen in both sexes but was stronger in women, showing a 22% increased time without dementia in women versus a 13% increased time in men with the recombinant versus the live vaccine.
As expected, the recombinant vaccine was associated with a lower risk for shingles disease vs the live vaccine (2.5% versus 3.5%), but women did not have a better response than men did in this respect.
"The better protection against shingles with the recombinant vaccine was similar in men and women, an observation that might be one reason to question the possible mechanism behind the dementia effect being better suppression of the herpes zoster virus by the recombinant vaccine," Harrison commented.
Though these findings are not likely to lead to any immediate changes in policy regarding the shingles vaccine, Harrison said it would be interesting to see whether uptake of the vaccine increased after this study.
He estimated that currently in the United Kingdom, about 60% of older adults choose to have the shingles vaccine. A 2020 study in the United States found that only about one third of US adults over 60 had received the vaccine.
"It will be interesting to see if that figure increases after these data are publicized, but I am not recommending that people have the vaccine specifically to lower their risk of dementia because of the caveats about the study that we have discussed," he commented.
Outside Experts Positive
Outside experts, providing comment to the Science Media Centre, welcomed the new research.
" The study is very well-conducted and adds to previous data indicating that vaccination against shingles is associated with lower dementia risk. More research is needed in future to determine why this vaccine is associated with lower dementia risk," Tara Spires-Jones, FMedSci, president of the British Neuroscience Association, said.
The high number of patients in the study and the adjustments for potential confounders are also strong points, noted Prof Andrew Doig, PhD, professor of biochemistry, University of Manchester, United Kingdom.
"This is a significant result, comparable in effectiveness to the recent antibody drugs for Alzheimer's disease," Doig said. "Administering the recombinant shingles vaccine could well be a simple and cheap way to lower the risk of Alzheimer's disease."
Doig noted that a link between herpes zoster infection and the onset of dementia has been suspected for some time, and a trial of the anti-viral drug, valacyclovir, against Alzheimer's disease is currently underway.
In regard to the shingles vaccine, he said a placebo-controlled trial would be needed to prove causality.
"We also need to see how many years the effect might last and whether we should vaccinate people at a younger age. We know that the path to Alzheimer's can start decades before any symptoms are apparent, so the vaccine might be even more effective if given to people in their 40s or 50s," he said.
Harrison and Taquet report no disclosures. Professor Doig is a founder, director, and consultant for PharmaKure Ltd, which works on Alzheimer's drugs and diagnostics. Other commentators declared no disclosures.